Suven Pharmaceuticals Ltd

Cohance Lifesciences Ltd has announced that its Board of Directors will convene on August 5, 2026. The primary agenda item for this meeting is to consider and approve the company's Unaudited Financial Results for both standalone and consolidated operations for the quarter ended June 30, 2026. The trading window for designated persons will remain closed until August 7, 2026.

Cohance Lifesciences Ltd has announced the closure of its trading window for designated persons and their immediate relatives, effective July 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will remain shut until 48 hours after the declaration of the company's unaudited financial results (standalone and consolidated) for the quarter ending June 30, 2026. The specific date for the board meeting to approve these results will be communicated later.

Cohance Lifesciences Ltd has responded to a BSE email seeking clarification on recent unusual trading volume in its shares. The company stated that there is no pending information or announcement that requires disclosure under SEBI Listing Regulations which could explain the volume behavior. They confirmed that all Unpublished Price Sensitive Information (UPSI) has been disclosed as and when required, in compliance with regulations. This clarification addresses potential market speculation regarding the stock's recent activity.

Cohance Lifesciences' promoters, Berhyanda Limited and Jusmiral Holdings Limited, have pledged a significant portion of their equity shares. A total of 207,974,582 equity shares, representing 54.36% of Cohance Lifesciences' total share capital, have been pledged to Catalyst Trusteeship Limited as an onshore security agent. This pledge secures term loan facilities availed by the promoters from various lenders. Additionally, covenants restrict the disposal and creation of further security on a larger block of 219,930,170 shares (57.49%) of the company held by the promoters. The shares of the borrowing entities themselves have also been pledged to an offshore security agent.

CSC Global Capital Markets (Singapore) Pte. Ltd., as security agent, has disclosed the release of encumbrances on 57.49% of Cohance Lifesciences Limited's equity shares. These shares were indirectly encumbered through covenants and offshore pledge agreements related to notes issued by promoters Berhyanda Limited and Jusmiral Holdings Limited. The encumbrances were released effective June 16, 2026, following the full repayment of the notes. This action lifts restrictions on disposal and security creation for these promoter holdings.

Cohance Lifesciences Limited has disclosed that its promoters, Berhyanda Limited and Jusmiral Holdings Limited, have encumbered a significant portion of their shareholding. CSC Global Capital Markets (Singapore) Pte Ltd, acting as agent and offshore security agent for lenders, has received the disclosure under SEBI SAST Regulations. This encumbrance affects 219,930,170 equity shares, representing 57.49% of the total share capital, due to term loan facilities availed by the promoters. The encumbrance, effective from June 16, 2026, includes restrictions on disposal and creation of further security.

Cohance Lifesciences Limited (formerly Suven Pharmaceuticals) has disclosed that its promoters, Jusmiral Holdings Limited and Berhyanda Limited, along with their respective holding entities Jusmiral Midco Limited and Berhyanda Midco Limited, have encumbered their shares. This action is in relation to a USD 285 million term loan facility. Jusmiral Holdings Limited has pledged 80,434,990 shares (21.02% of total capital), and both promoters have agreed to covenants restricting disposal and security creation on their shareholdings. The total promoter holding in Cohance Lifesciences is 57.49%.

Cohance Lifesciences Limited (formerly Suven Pharmaceuticals) has received disclosures under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, from its promoters Jusmiral Holdings Ltd and Berhyanda Ltd, along with their respective subsidiaries Jusmiral Midco Ltd and Berhyanda Midco Ltd. These disclosures pertain to encumbrances created on shares, including restrictions on disposal and creation of security, as per a Notes Purchase Agreement and subsequent share pledge deeds effective from June 18, 2024. The filings indicate a complex structure involving multiple entities and financial agreements that impact the promoters' shareholding.

Cohance Lifesciences Limited (formerly Suven Pharmaceuticals) has disclosed that its promoters, Jusmiral Holdings Ltd and Berhyanda Ltd, along with their respective holding entities (Jusmiral Midco Ltd and Berhyanda Midco Ltd), have encumbered their shares. This action is related to a USD 285 million term loan facility secured by Jusmiral Holdings and Berhyanda Limited. Specifically, Jusmiral Holdings has pledged 80,434,990 equity shares (21.02% of total capital) in Cohance Lifesciences to secure its portion of the loan. Jusmiral Midco and Berhyanda Midco have also agreed to covenants and created pledges on their shareholdings in Jusmiral Holdings and Berhyanda Limited, respectively, restricting disposal and further encumbrance.

Cohance Lifesciences Ltd announced the resignation of Mr. Himanshu Agarwal from his roles as Whole-time Director and Chief Financial Officer (Key Managerial Personnel). Mr. Agarwal is stepping down to pursue a new professional opportunity outside the company. His last day of employment will be at the close of business hours on September 13, 2026. The company confirmed that there are no other material reasons for his resignation. He committed to ensuring a smooth handover of responsibilities during his remaining tenure.